MyNorth Guardian Investment Options

6 November 2026

Issue of Supplementary Product Disclosure Statement

We will be issuing a Supplementary Product Disclosure Statement ('SPDS') for investors in the MyNorth Guardian Investment Options ('the Investment Options) as shown below. The SPDS will be available on the website from **6 November 2026.**

Investment Options	ARSN	APIR code	PDS & SPDS location
MyNorth Guardian Max 85[1]	163 411 318	IPA0167AU	northonline.com.au
MyNorth Guardian Max 100[2]	163 411 274	IPA0168AU	

The key change is the removal of references to the North Managed Volatility Moderately Defensive Fund (also referred to as the MyNorth Guardian Max 60) (AFSL 163 411 461, APIR code IPA0169AU) and related consequential changes, due to its termination on 6 November 2026, which we've communicated separately today.

Full details of the changes can be found in the SPDS. As always, we recommend you read this document together with the original PDS to understand the main benefits and risks of investing, along with other features of the Investment Options. Indirect investors should also consider the Target Market Determination (TMD) for an Investment Option before making an investment decision to consider whether an Investment Option is and remains appropriate for them. A TMD in respect of an Investment Option is available at amp.com.au/investments-tmd.

Is any action required by investors?

No action is required by investors.

[1] Registered name: "North Managed Volatility Balanced Fund"
[2] Registered name: "North Managed Volatility Growth Fund"

We're here to help

If you have any questions about this update, please contact your Client Account Manager or our Investor Services Team via email at ampinvestments@amp.com.au or on 133 267, between 8.30am and 5.30pm (Sydney time) Monday to Friday.

Yours sincerely,



Anna Hill

Head of Products & Clients
AMP Investments

On behalf of the responsible entity of the Investment Options, ipac Asset Management Limited (ABN 22 003 257 225, AFSL 234655).

Important Notice: ipac Asset Management Limited (ABN 22 003 257 225, AFSL 234655) (IAML) is the responsible entity of the MyNorth Guardian Investment Options ('the Investment Options') and is the issuer of the units in the Investment Options. To invest in the Investment Options, investors will need to obtain the current Product Disclosure Statement (PDS) or other offer document for the relevant Investment Options from National Mutual Funds Management Ltd (ABN 32 006 787 720, AFSL 234652) (NMFM). The PDS or offer document contains important information about investing in the Investment Options and it is important that investors read the PDS or offer document before making a decision about whether to acquire, or continue to hold or dispose of units in the Investment Options. A target market determination has been made in respect of the Investment Options and is available at amp.com.au/investments-tmd. Neither NMFM, IAML nor any other company in the AMP Group guarantees the repayment of capital or the performance of any product or any particular rate of return referred to in this document. Past performance is not a reliable indicator of future performance. Investors should read the PDS for the Investment Options before making a decision regarding the Investment Options. While every care has been taken in the preparation of this document, NMFM makes no representation or warranty as to the accuracy or completeness of any statement in it including without limitation, any forecasts. This communication has been prepared for the purpose of providing general information, without taking account of any particular investor's objectives, financial situation or needs. Investors should, before making any investment decisions, consider the appropriateness of the information in this communication, and seek professional advice, having regard to their objectives, financial situation and needs. This document is solely for the use of the party to whom it is provided and must not be provided to any other person or entity without the express written consent of NMFM.